Page last updated: 2024-09-05

erlotinib hydrochloride and Dizzyness

erlotinib hydrochloride has been researched along with Dizzyness in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Evans, TR; Kalofonos, HP; Koutras, AK; Makatsoris, T; Mastronikolis, NS; Papadeas, ES	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Dizzyness

Article	Year
Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dizziness; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Hearing; Hearing Loss, Sensorineural; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Tinnitus; Treatment Failure	2008

Article

Year

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.

Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:6

Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dizziness; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Hearing; Hearing Loss, Sensorineural; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Tinnitus; Treatment Failure

2008